101 / 101
S
omatic
mutations
in
breast
and
serous
ovarian
cancer
young
patients
:
a
systematic
review
and
meta
-
analysis
R
ev
A
ssoc
M
ed
B
ras
2015; 61(5):474-483
483
69. Chen FM, Hou MF, Wang JY, Chen TC, Chen DC, Huang SY, et al. High
frequency of G/C transversion on
P53
gene alterations in breast cancers
from Taiwan. Cancer Lett. 2004; 207(1):59-67.
70. Van Emburgh BO, Hu JJ, Levine EA, Mosley LJ, Case LD, Lin HY, et al.
Polymorphisms in drug metabolism genes, smoking, and
P53
mutations
in breast cancer. Mol Carcinog. 2008; 47(2):88-99.
71.
Bozhanov SS, Angelova SG,
KRAS
teva ME, Markov TL, Christova SL, Gavrilov
IG, et al. Alterations in
P53
,
BRCA1
, ATM,
PIK3CA
, and HER2 genes and
their effect in modifying clinicopathological characteristics and overall
survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol.
2010; 136(11):1657-69.
72.
Jiang YZ, Yu KD, Zuo WJ, Peng WT, Shao ZM.
GATA3
mutations define a
unique subtype of luminal-like breast cancer with improved survival. Cancer.
2014; 120(9):1329-37.
73.
Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, et al.
Mutational characterization of individual breast tumors:
TP53
and PI3K
pathway genes are frequently and distinctively mutated in different subtypes.
Breast Cancer Res Treat. 2012; 132(1):29-39.
74. FujitaM, Enomoto T, InoueM, Tanizawa O, Ozaki M, Rice JM, et al. Alteration
of the
P53
tumor suppressor gene occurs independently of K-ras activation and
more frequently in serous adenocarcinomas than in other common epithelial
tumors of the human ovary. Jpn J Cancer Res. 1994; 85(12):1247-56.
75.
Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN.
Comparative analysis of loss of heterozygosity of specific chromosome 3,
13, 17, and X loci and
TP53
mutations in human epithelial ovarian cancer.
Mol Carcinog. 2002; 34(2):78-90.
76.
Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, et al.
Prognostic significance of
P53
mutation in suboptimally resected advanced
ovarian carcinoma treated with the combination chemotherapy of paclitaxel
and carboplatin. Cancer Lett. 2006; 241(2):289-300.
77.
Høgdall EV, Høgdall CK, Blaakaer J, Christensen L, Bock JE, Vuust J, et al.
K-ras alterations in Danish ovarian tumour patients. From the Danish
“Malova” Ovarian Cancer study. Gynecol Oncol. 2003; 89(1):31-6.
78. Takahashi H, Behbakht K, McGovern PE, Chiu HC, Couch FJ, Weber BL, et
al. Mutation analysis of the
BRCA1
gene in ovarian cancers. Cancer Res.
1995; 55(14):2998-3002.